Selective CD47 targeting with a bispecific antibody.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

1. Multi-targeted immunotherapeutics to treat B cell malignancies.Journal of controlled release : official journal of the Controlled Release Society · 2023
   Review
2. Targeting macrophages in hematological malignancies: recent advances and future directions.Journal of hematology & oncology · 2022
   Review
3. CD47 as a promising therapeutic target in oncology.Frontiers in immunology · 2022
   Review
4. Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies.Experimental hematology & oncology · 2021
   Review
5. Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1.mAbs
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as